Human engineered cardiac tissues created using induced pluripotent stem cells reveal functional characteristics of BRAF-mediated hypertrophic cardiomyopathy

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Cashman, Timothy J ^a   Josowitz, Rebecca ^a   Johnson, Bryce V ^a   Gelb, Bruce D ^a   Costa, Kevin D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; B RAF KINASE;

ANIMAL CELL; ANP GENE; ARRHYTHMOGENESIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL POPULATION; CONJUGATION; CONTROLLED STUDY; DIASTOLE; DISEASE MODEL; EMBRYO; GENE; GENE EXPRESSION; GENE MUTATION; HEART CONTRACTION; HEART MUSCLE CELL; HEART MUSCLE EXCITABILITY; HEART MUSCLE RELAXATION; HEART PACING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; LEOPARD SYNDROME; MOUSE; MUSCLE TWITCH; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRINCIPAL COMPONENT ANALYSIS; STROMA CELL; TISSUE ENGINEERING; WILD TYPE; CARDIAC MUSCLE CELL; CYTOLOGY; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ATRIAL NATRIURETIC FACTOR; CARDIOMYOPATHY, HYPERTROPHIC; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MUTATION; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS B-RAF; TISSUE ENGINEERING;

EID: 84958225498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146697     Document Type: Article

References (43)

1. Arad M, Seidman JG, Seidman CE. Phenotypic diversity in hypertrophic cardiomyopathy. Hum. Mol. Genet. 2002;11:2499-506. PMID: 12351586
2. Konno T, Chang S, Seidman JG, Seidman CE. Genetics of hypertrophic cardiomyopathy. Curr. Opin. Cardiol. 2010;25:205-9. doi: 10.1097/HCO.0b013e3283375698 PMID: 20124998
3. Schoenfeld JR, Vasser M, Jhurani P, Ng P, Hunter JJ, Ross J, et al. Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. Journal of Molecular and Cellular Cardiology 1998;30:2269-80. PMID: 9925364
4. Mortazavi M. Sudden cardiac death in young athletes. Adv Pediatr 2013;60:201-15. doi: 10.1016/j. yapd.2013.04.015 PMID: 24007846
5. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014;64:83-99. doi: 10.1016/j.jacc.2014.05.003 PMID: 24998133
6. Shephard R, Semsarian C. Role of animal models in HCM research. J. of Cardiovasc. Trans. Res. 2009;2:471-82.
7. Nonaka M, Morimoto S. Experimental models of inherited cardiomyopathy and its therapeutics. World J Cardiol 2014;6:1245-51. doi: 10.4330/wjc.v6.i12.1245 PMID: 25548614
8. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang Y-S, Schaniel C, Lee D-F, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010;465:808-12. doi: 10.1038/nature09005 PMID: 20535210
9. Turnbull IC, Karakikes I, Serrao GW, Backeris P, Lee J-J, Xie C, et al. Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J 2014;28:644-54. doi: 10. 1096/fj.13-228007 PMID: 24174427
10. Hirt MN, Sörensen NA, Bartholdt LM, Boeddinghaus J, Schaaf S, Eder A, et al. Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res. Cardiol. 2012;107:307. doi: 10.1007/s00395-012-0307-z PMID: 23099820
11. de Lange WJ, Hegge LF, Grimes AC, Tong CW, Brost TM, Moss RL, et al. Neonatal mouse-derived engineered cardiac tissue: a novel model system for studying genetic heart disease. Circulation Research 2011;109:8-19. doi: 10.1161/CIRCRESAHA.111.242354 PMID: 21566213
12. Sala V, Gallo S, Leo C, Gatti S, Gelb BD, Crepaldi T. Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. Mol. Med. 2012;18:938-47. doi: 10.2119/molmed.2011.00512 PMID: 22576369
13. Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet 2013;14:355-69. doi: 10.1146/annurev-genom-091212-153523 PMID: 23875798
14. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007;116:1413-23. PMID: 17875982
15. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000;19:6341-50. PMID: 11101507
16. Muslin AJ. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin. Sci. 2008;115:203-18. doi: 10.1042/CS20070430 PMID: 18752467
17. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol. Endocrinol. 2004;18:2344-54. PMID: 15205471
18. Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, et al. The cardiofaciocutaneous syndrome. J. Med. Genet. 2006;43:833-42. PMID: 16825433
19. Armour CM, Allanson JE. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J. Med. Genet. 2008;45:249-54. PMID: 18039946
20. Allanson JE, Annerén G, Aoki Y, Armour CM, Bondeson M-L, Cave H, et al. Cardio-facio-cutaneous syndrome: does genotype predict phenotype? Am J Med Genet CSemin Med Genet 2011;157C:129-35. doi: 10.1002/ajmg.c.30295 PMID: 21495173
21. Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum. Mutat. 2009;30:695-702. doi: 10.1002/humu.20955 PMID: 19206169
22. Rodriguez-Viciana P, Rauen KA. Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. Meth. Enzymol. 2008;438:277-89. doi: 10.1016/S0076-6879 (07) 38019-1 PMID: 18413255
23. Yoon G, Rosenberg J, Blaser S, Rauen KA. Neurological complications of cardio-facio-cutaneous syndrome. Dev Med Child Neurol 2007;49:894-9. PMID: 18039235
24. Serrao GW, Turnbull IC, Ancukiewicz D, Kim DE, Kao E, Cashman TJ, et al. Myocyte-Depleted Engineered Cardiac Tissues Support Therapeutic Potential of Mesenchymal Stem Cells. Tissue Engineering Part A 2012;18:1322-33. doi: 10.1089/ten. TEA.2011.0278 PMID: 22500611
25. Schaaf S, Shibamiya A, Mewe M, Eder A, Stöhr A, Hirt MN, et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS ONE 2011;6:e26397. doi: 10.1371/journal.pone.0026397 PMID: 22028871
26. Ringnér M. What is principal component analysis? Nat Biotechnol 2008;26:303-4. doi: 10.1038/nbt0308-303 PMID: 18327243
27. Abdi H, Williams LJ. Principal component analysis. WIREsComp Stat 2010;2:433-59.
28. Dubois NC, Craft AM, Sharma P, Elliott DA, Stanley EG, Elefanty AG, et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol 2011;29:1011-8. doi: 10.1038/nbt.2005 PMID: 22020386
29. Gago-Lopez N, Awaji O, Zhang Y, Ko C, Nsair A, Liem D, et al. THY-1 receptor expression differentiates cardiosphere-derived cells with divergent cardiogenic differentiation potential. Stem Cell Reports 2014;2:576-91. doi: 10.1016/j.stemcr.2014.03.003 PMID: 24936447
30. Wang J, Chen A, Lieu DK, Karakikes I, Chen G, Keung W, et al. Effect of engineered anisotropy on the susceptibility of human pluripotent stem cell-derived ventricular cardiomyocytes to arrhythmias. Biomaterials 2013;34:8878-86. doi: 10.1016/j.biomaterials.2013.07.039 PMID: 23942210
31. Tulloch NL, Muskheli V, Razumova MV, Korte FS, Regnier M, Hauch KD, et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circulation Research 2011;109:47-59. doi: 10.1161/CIRCRESAHA.110.237206 PMID: 21597009
32. Nunes SS, Miklas JW, Liu J, Aschar-Sobbi R, Xiao Y, Zhang B, et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Meth 2013;10:781-7.
33. Thavandiran N, Dubois N, Mikryukov A, Massé S, Beca B, Simmons CA, et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc Natl Acad Sci USA 2013;110:E4698-707. doi: 10.1073/pnas.1311120110 PMID: 24255110
34. Ma Z, Koo S, Finnegan MA, Loskill P, Huebsch N, Marks NC, et al. Three-dimensional filamentous human diseased cardiac tissue model. Biomaterials 2014;35:1367-77. doi: 10.1016/j.biomaterials.2013.10.052 PMID: 24268663
35. Komae H, Sekine H, Dobashi I, Matsuura K, Ono M, Okano T, et al. Three-dimensional functional human myocardial tissues fabricated from induced pluripotent stem cells. J Tissue Eng Regen Med 2015;
36. Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kamp TJ. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circulation Research 2012;111:344-58. doi: 10.1161/CIRCRESAHA.110.227512 PMID: 22821908
37. Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nature Medicine 2014;20:616-23. doi: 10.1038/nm.3545 PMID: 24813252
38. Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: state of the art. Circulation Research 2014;114:354-67. doi: 10.1161/CIRCRESAHA.114.300522 PMID: 24436431
39. Wilkins BJ, Dai Y-S, Bueno OF, Parsons SA, Xu J, Plank DM, et al. Calcineurin/NFATcoupling participates in pathological, but not physiological, cardiac hypertrophy. Circulation Research 2004;94:110-8. PMID: 14656927
40. Zheng M, Dilly K, Santos Cruz Dos J, Li M, Gu Y, Ursitti JA, et al. Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol 2004;286:H424-33. PMID: 12969887
41. Ruan H, Mitchell S, Vainoriene M, Lou Q, Xie L-H, Ren S, et al. Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy. Circulation 2007;116:596-605. PMID: 17646583
42. Kirkton RD, Bursac N. Genetic engineering of somatic cells to study and improve cardiac function. Europace 2012;14 Suppl 5:v40-9. doi: 10.1093/europace/eus269 PMID: 23104914
43. +channels by B-RAF. PLoSONE 2014;9:e87457. doi: 10.1371/journal.pone.0087457 PMID: 24475291